-- 蘇州日博生命科技（香港証券取引所：6938）は、主力製品である心房細動患者の脳卒中予防薬「ボルトシラン」について、欧州医薬品庁（EMA）に第2b相臨床試験の申請を行ったと、火曜日に香港証券取引所に提出した書類で明らかにした。 ボルトシランは凝固因子XIを標的として凝固活性を低下させ、出血リスクを低減しながら血栓塞栓症予防効果を発揮する可能性があると、同書類は述べている。
Related Articles
Asia
Ginlong Technologies' 2025 Profit Rises 7.5%; Shares Slump 16%
Ginlong Technologies' (SHE:300763) net profit attributable to shareholders in 2025 jumped 7.5% year on year to 743.2 million yuan from 691.2 million yuan, according to a Shenzhen bourse filing on Monday.Earnings per share edged up to 1.88 yuan from 1.75 yuan.The Chinese PV string inverter company's revenue rose 6.3% to 6.95 billion yuan from 6.54 billion yuan a year earlier.Shares of Ginlong plunged 16% in late-afternoon trade on Monday.
$SHE:300763
Asia
CTOS Digital Seeks 10% Share Buyback Mandate
CTOS Digital (KLSE:CTOS) will seek shareholders' approval to renew authority to repurchase up to 10% of the issued shares of the company, according to a Friday Malaysian bourse disclosure.Shares gained over 2% in Monday's midday trade.The holding company of credit rating agencies in Malaysia will table a resolution to renew the share buyback authority in the company's upcoming annual general meeting,CTOS will release a statement containing details of the repurchase plan with shareholders in due time, it noted.
$KLSE:CTOS
Asia
Adani Green Energy's Consolidated Profit Rises in Fiscal Q4
Adani Green Energy (NSE:ADANIGREEN, BOM:541450) consolidated attributable net profit jumped to 5.14 billion Indian rupees in the fiscal fourth quarter from 3.83 billion rupees a year ago, according to a Friday filing by the renewable energy company.Earnings per share for the quarter ended March 31 climbed to 2.33 rupees from 1.26 rupees a year earlier.Power supply revenue increased year on year to 30.9 billion rupees from 26.7 billion rupees while sale of goods fell to 2.34 billion rupees from 3.85 billion rupees.Shares of the company rose nearly 1% in Monday's trade.
$BOM:541450$NSE:ADANIGREEN